OGT Expands Product Portfolio with Complete Library Preparation Solution
OGT has announced the expansion of its SureSeq portfolio with a complete library preparation solution for hybridization-based target capture in NGS.
Oxford Gene Technology (OGT) has announced the expansion of its SureSeq portfolio with a complete library preparation solution for hybridization-based target capture in next-generation sequencing (NGS).
Through the expansion, which includes an updated and refined library preparation workflow, as well as a new, ready-to-use hybridization and wash buffer, OGT has made its MGS coverage and expertise more accessible. The SureSeq NGS portfolio features targeted panels, library preparation kits, and a software package.
“With this expansion of our SureSeq portfolio, we have further broken down the barriers for hybridization in NGS, making it quicker, easier, and more flexible, while also delivering enormous benefits to researchers in terms of data quality,” said John Anson, CEO of OGT in a June 13, 2019 press release. “OGT has a reputation for quality and expertise and together with Sysmex we see NGS as a key future technology. As part of a large, global IVD company, we are exploring many exciting possibilities, and it is our aim that future development plans in this area will be transformative for our customers.”
Source: OGT
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
